Product Description
Since last many years Saintroy Lifescience is leading manufacture,export and supplier of Erlotinib Tablets from Surat, Gujarat, India. Erlotinib Tablets it is used for NSCLC with mutations in the epidermal growth factor receptor (EGFR) either an exon 19 deletion (del19) or exon 21 (L858R) substitution mutation which has spread to other parts of the body
Tags: Erlotinib Tablets Manufacturer, Erlotinib Tablets exporter, Erlotinib Tablets supplier, Erlotinib Tablets, Erlotinib potassium, whogmp approved,Erlotinib potassium tablets manufacturer and supplier, Erlotinib Tablets distributor, Erlotinib Tablets drop shipper,Erlotinib Tablets 150 mg, Erlotinib Tablets 150 mg supplier, Erlotinib Tablets 150mg.
ISO/GMP/c-GMP/WHOGMP/NAFDAC approved, PPB Kenya approved/USFDA approved/EUGMP approved/MOH Iran approved manufacturing facility in Gujarat, India.
Registration: Saintroy Lifescience is interested in registration of own brand or customer brands in ministry of health of clients country and we also provide the products samples, COA, COPP, ACTD or CTD Dossier, DMF, Manufacturing license, Free sale certificate and other required documents.
Export Country : Saintroy Lifescience export Erlotinib Tablets to USA, Canada, Germany, Europe,France, Ghana, Nigeria, Kenya, Senegal, Sudan, UAE, Kuwait, Dubai, Cameroon,Lebanon, Peru, Chile, Somalia, Philippines, Myanmar, Maldives, Thailand,Singapore, Malaysia, Hong Kong, China, Zimbabwe, Togo, Burkina Faso, Niger,Guinea Bissau, Congo, Democratic of republic, Ivory Costa, Oman, Guatemala,Nicaragua, Salvador, Qatar, Costa Rica, Panama, Cuba, Colombia, Bolivia,Argentine, Algeria, Guyana, Morocco, Jordan, Bahrain, Iran, Egypt, Kyrgyzstan,Uzbekistan, Kazakhstan.
Effective Oral Therapy for CancerErlotinib Tablets provide a targeted method to manage non-small cell lung cancer (NSCLC) and pancreatic cancer. The oral route allows for convenient at-home administration, maximizing patient comfort. Each tablet is created to meet stringent USP/EP/BP pharmaceutical standards, ensuring consistent efficacy, quality, and safety.
Comprehensive Packaging OptionsErlotinib Tablets come securely packaged in either blister packs, Alu-Alu packs, or boxes, maintaining product integrity and extending shelf life. The careful packaging safeguards the medication from moisture and contamination, making it ideal for supply to hospitals, pharmacies, and export requirements.
Usage and Safety ConsiderationsPrescription is mandatory for Erlotinib Tablets; only qualified healthcare professionals should guide therapy. As with all potent anti-cancer medication, patients with known hypersensitivity to erlotinib or its excipients must not use this product. Patients with liver or kidney impairment and those at risk for interstitial lung disease require special caution during therapy.
FAQ's of Erlotinib Tablets:
Q: How should Erlotinib Tablets be administered for optimal effectiveness?
A: Erlotinib Tablets should be taken orally, exactly as prescribed by a healthcare professional. It's important to follow dosing instructions closely, often on an empty stomach or as instructed by your doctor, to ensure consistent drug absorption and effectiveness.
Q: What are the primary uses of Erlotinib Tablets?
A: These tablets are indicated mainly for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. Your doctor will determine the appropriate dosage and course duration based on your specific medical condition.
Q: When should Erlotinib Tablets be avoided?
A: Erlotinib should not be used by individuals with known hypersensitivity to erlotinib hydrochloride or any tablet excipients. It is also contraindicated in certain patients as assessed by a medical professional.
Q: Where should Erlotinib Tablets be stored to maintain their quality?
A: Store the tablets in a cool, dry place, away from direct sunlight and moisture, and ensure they remain in their original packaging until use. Proper storage helps preserve their potency throughout the two-year shelf life.
Q: What precautions should patients with liver or kidney problems observe while on Erlotinib?
A: Patients with hepatic or renal impairment should use Erlotinib with caution, as advised by their healthcare provider. Regular monitoring may be necessary to adjust the dose and manage any potential side effects.
Q: How does the packaging type benefit the distribution and long-term use of Erlotinib Tablets?
A: The choice of blister, Alu-Alu packs, or boxes protects the tablets from environmental exposure, reduces contamination risk, and ensures long shelf life. These packaging types are particularly suitable for wholesale, export, and distribution.
Q: What advantages do Erlotinib Tablets offer compared to other treatments?
A: Erlotinib provides a targeted mechanism of action, which can result in effective management of certain cancers with a convenient oral regimen, and meets recognized pharmaceutical quality standards, ensuring reliability for both prescribers and patients.